Related references
Note: Only part of the references are listed.Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
Alyssa A. Toorop et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Ocrelizumab initiation in patients with MS A multicenter observational study
Erik Ellwardt et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Anti-JCV antibody index does not change during ocrelizumab-treatment
Torge Rempe et al.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2020)
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle et al.
NEUROLOGY (2019)
Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
I Dekker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EVIDENCE-BASED GUIDELINES MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients
Mike P. Wattjes et al.
NATURE REVIEWS NEUROLOGY (2015)
Share Paper
